Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2670216 | 1.00 | MEN1 (0.34) | MEN1MAPK1KMT2AP2RX7 | |
| SCHEMBL2670225 | 0.82 | MEN1 (0.35) | MEN1MAPK1KMT2AP2RX7 | |
| SCHEMBL4749107 | 0.82 | MEN1 (0.35) | MEN1MAPK1KMT2AP2RX7 | |
| SCHEMBL14139852 | 0.82 | MEN1 (0.35) | MEN1MAPK1KMT2AP2RX7 | |
| SCHEMBL2670123 | 0.80 | MEN1 (0.34) | MEN1MAPK1KMT2A | |
| SCHEMBL2670360 | 0.80 | MEN1 (0.34) | MEN1MAPK1KMT2A | |
| SCHEMBL14140026 | 0.80 | MEN1 (0.34) | MEN1MAPK1KMT2A | |
| SCHEMBL2670327 | 0.76 | MEN1 (0.37) | MEN1MAPK1KMT2A | |
| SCHEMBL4748450 | 0.76 | MEN1 (0.37) | MEN1MAPK1KMT2A | |
| SCHEMBL2670367 | 0.74 | MEN1 (0.35) | MEN1MAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140142096-A1 | Fused Substituted Aminopyrrolidine Derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-05-22 | — | — | US | disclosed |
| US-20130029977-A9 | Fused substituted aminopyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED | 2013-01-31 | — | — | US | disclosed |
| US-20120108582-A1 | Fused substituted aminopyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108582-A1 | Fused substituted aminopyrrolidine derivative | NQO2, QDPR, IL4I1 | MEN1 3591/4885MAPK1 2614/4885KMT2A 2847/4885 |
| US-20140142096-A1 | Fused Substituted Aminopyrrolidine Derivative | NQO2, QDPR, IL4I1 | MEN1 3591/4885MAPK1 2614/4885KMT2A 2847/4885 |
| US-20130029977-A9 | Fused substituted aminopyrrolidine derivative | NQO2, QDPR, IL4I1 | MEN1 3591/4885MAPK1 2614/4885KMT2A 2847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.